This is more than double the 14% reduction that the same study found with naltrexone, which was the best-performing medication approved for treatment of alcohol use disorder in that analysis
Small intestinal bacterial overgrowth (SIBO) has been anecdotally reported in semaglutide users, potentially triggered by the slow intestinal transit that GLP-1 agonists create
UV rays damage the DNA in skin cells, potentially causing them to grow uncontrollably and develop into cancerous tumors
All articles When to Titrate Up on Your GLP-1 Dose: Signs You're Ready for the Next Step Reading time: 11 min Author Published on Updated on Weight loss Get expert guidance and a personalized care plan designed around you
[DOI] [PubMed] [Google Scholar] 73.Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR
Expand Your Knowledge A Guide for Supporting Clients on Anti-obesity Medications Gain essential knowledge and skills to effectively support clients taking anti-obesity medications (AOMs) and navigate the evolving health and fitness landscape
